CSS
KPTI icon

Cubist Systematic Strategies’s Karyopharm Therapeutics KPTI Stock Holding History

Cubist Systematic Strategies’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21,920
Closed -$222K – 3195
2024
Q4 		$222K Sell
21,920
-11,162
-34% -$135K ﹤0.01% 2528
2024
Q3 		$412K Sell
33,082
-4,850
-13% -$60.3K ﹤0.01% 2286
2024
Q2 		$494K Buy
+37,932
New +$628K ﹤0.01% 2136
2024
Q1 		– Sell
-312
Closed -$4.05K – 4019
2023
Q4 		$4.05K Buy
+312
New +$4.2K ﹤0.01% 3432
2023
Q3 		– Sell
-10,667
Closed -$286K – 3660
2023
Q2 		$286K Buy
+10,667
New +$459K ﹤0.01% 2652
2023
Q1 		– Sell
-32,667
Closed -$1.67M – 4179
2022
Q4 		$1.67M Buy
32,667
+26,776
+455% +$1.86M 0.01% 2010
2022
Q3 		$482K Sell
5,891
-6,808
-54% -$509K ﹤0.01% 3190
2022
Q2 		$859K Buy
12,699
+1,933
+18% +$177K 0.01% 2596
2022
Q1 		$1.19M Sell
10,766
-26,803
-71% -$3.34M 0.01% 1905
2021
Q4 		$3.62M Buy
37,569
+31,169
+487% +$3.11M 0.03% 869
2021
Q3 		$559K Buy
6,400
+3,266
+104% +$339K 0.01% 1955
2021
Q2 		$485K Buy
3,134
+1,135
+57% +$165K 0.01% 2035
2021
Q1 		$315K Buy
+1,999
New +$421K ﹤0.01% 2224
2020
Q4 		– Sell
-5,836
Closed -$1.28M – 2634
2020
Q3 		$1.28M Buy
5,836
+2,692
+86% +$658K 0.02% 1186
2020
Q2 		$893K Buy
3,144
+1,786
+132% +$528K 0.02% 1246
2020
Q1 		$391K Sell
1,358
-3,082
-69% -$850K 0.01% 1379
2019
Q4 		$1.28M Buy
+4,440
New +$963K 0.02% 1006
2019
Q3 		– Sell
-5,634
Closed -$506K – 2337
2019
Q2 		$506K Buy
5,634
+4,441
+372% +$357K 0.01% 1465
2019
Q1 		$105K Sell
1,193
-1,289
-52% -$143K ﹤0.01% 1986
2018
Q4 		$349K Buy
2,482
+1,152
+87% +$194K 0.02% 1177
2018
Q3 		$340K Buy
1,330
+753
+131% +$208K 0.02% 1081
2018
Q2 		$147K Sell
577
-1,115
-66% -$276K 0.01% 1446
2018
Q1 		$341K Buy
1,692
+1,628
+2,544% +$325K 0.02% 1062
2017
Q4 		$9K Buy
+64
New +$10.3K ﹤0.01% 1855

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Cubist Systematic Strategies's KPTI Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 21,920 shares — an estimated $222K sold.

Cubist Systematic Strategies first reported a position in KPTI in Q4 2017 and held it in 24 quarters. The position peaked at $3.62M in Q4 2021. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 21,920 Karyopharm Therapeutics shares in Q1 2025, an estimated $222K.
  • Cubist Systematic Strategies first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 24 quarters.
  • Cubist Systematic Strategies's Karyopharm Therapeutics position peaked at $3.62M in Q4 2021.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.